Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures

Protein Science

Volumn 20, Issue 2, 2011, Pages 428-436

  Kuglstatter, Andreas ^a   Wong, April ^b   Tsing, Stan ^g   Lee, Simon W ^a   Lou, Yan ^a   Villaseñor, Armando G ^c   Bradshaw, J Michael ^d   Shaw, David ^e   Barnett, Jim W ^g   Browner, Michelle F ^f  

^a HOFFMANN LA ROCHE INC   (United States)

^b JOINT BIOENERGY INSTITUTE   (United States)

^c GILEAD SCIENCES   (United States)

^d ELAN PHARMACEUTICALS   (United States)

^e GENENTECH INC   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g NONE

Author keywords

Activation loop; Bruton's tyrosine kinase; DFG out; Helix C; Phosphorylation; Protein crystallography; R406; Structure based drug design

Indexed keywords

ADENOSINE TRIPHOSPHATE; BRUTON TYROSINE KINASE; LIGAND;

ALPHA HELIX; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SRC HOMOLOGY DOMAIN;

ANIMALS; MICE; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OXAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIDINES; X-RAY DIFFRACTION;

EID: 79251564897     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.575     Document Type: Article

References (27)

1. Brunner C, Muller B, Wirth T (2005) Bruton's tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 20:945-955. (Pubitemid 40932612)
2. Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Heinonen JE, Berglof A, Mohamed AJ, Nore BF, Vihinen M, Smith CI (2005) Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200-215.
3. Pan Z (2008) Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect 21:357-362.
4. Uckun FM, Qazi S (2010) Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity. Expert Opin Ther Pat 20:1457-1470.
5. Mao C, Zhou M, Uckun FM (2001) Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 276:41435-41443.
6. Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E, Jenkins TJ, Romanowski MJ, Baker DP, Silvian LF (2010) Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci 19:429-439.
7. Cowan-Jacob SW, Mobitz H, Fabbro D (2009) Structural biology contributions to tyrosine kinase drug discovery. Curr Opin Cell Biol 21:280-287.
8. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109:275-282.
9. Jacobs MD, Caron PR, Hare BJ (2008) Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins 70:1451-1460.
10. Boyd E, Brookfield F, Georges G, Goller B, Huensch S, Rueger P, Rueth M, Scheiblich S, Schuell C, Von Der Saal W, Warne J, Weigand S (2006) Preparation of novel phthalazinone derivatives as Aurora-A kinase inhibitors for use against illnesses such as cancer. Patent Application WO 2006032518 A1.
11. Goldstein DM, Rueth M (2007) Methods of inhibiting BTK and SYK protein kinases using (pyrazolylamino) phthalazines and their preparation. Patent Application US 2007219195 A1.
12. Kutach AK, Villasenor AG, Lam D, Belunis C, Janson C, Lok S, Hong LN, Liu CM, Deval J, Novak TJ, Barnett JW, Chu W, Shaw D, Kuglstatter A (2010) Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem Biol Drug Des 76:154-163.
13. 10-helix. Trends Biochem Sci 16:350-353.
14. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303-1312.
15. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998-1008.
16. Norman P (2009) A novel Syk kinase inhibitor suitable for inhalation: R-343(?)-WO-2009031011. Expert Opin Ther Pat 19:1469-1472.
17. Villasenor AG, Kondru R, Ho H, Wang S, Papp E, Shaw D, Barnett JW, Browner MF, Kuglstatter A (2009) Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des 73: 466-470.
18. Goldstein DM, Alfredson T, Bertrand J, Browner MF, Clifford K, Dalrymple SA, Dunn J, Freire-Moar J, Harris S, Labadie SS, La FJ, Lapierre JM, Larrabee S, Li F, Papp E, McWeeney D, Ramesha C, Roberts R, Rotstein D, San PB, Sjogren EB, So OY, Talamas FX, Tao W, Trejo A, Villasenor A, Welch M, Welch T, Weller P, Whiteley PE, Young K, Zipfel S (2006) Discovery of S-[5-amino-1-(4-fluorophenyl) -1H-pyrazol-4-yl]-[3-(2,3- dihydroxypropoxy)ph enyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J Med Chem 49:1562-1575.
19. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53:2345-2353.
20. Engh R, Hertenberger H, Honold K, Masjost B, Rueger P, Schaefer W, Scheiblich S, Schwaiger M (2007) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents. Patent Application WO 2007017143.
21. Guo S, Wahl MI, Witte ON (2006) Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families. Int Immunol 18:79-87. (Pubitemid 43057039)
22. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxybeta- methyl-N-(2,5-dibromophenyl)propenamide]. J Biol Chem 274:9587-9599.
23. Otwinowski Z, Minor W, Processing of X-ray diffraction data collected in oscillation mode. In: Carter CWJ, Sweet RM, Eds. (1997) Macromolecular crystallography, part A. New York: Academic Press, pp 307-326.
24. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61:458-464.
25. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximumlikelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255.
26. Gerber PR (1992) Peptide mechanics: a force field for peptides and proteins working with entire residues as small unites. Biopolymers 32:1003-1017.
27. Dinh M, Grunberger D, Ho H, Tsing SY, Shaw D, Lee S, Barnett J, Hill RJ, Swinney DC, Bradshaw JM (2007) Activation mechanism and steady state kinetics of Bruton's tyrosine kinase. J Biol Chem 282:8768-8776.